A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia
Introduction: Treatment of relapsed and refractory (R/R) B acute lymphoblastic leukemia (B-
ALL) represents an unmet medical need in children and adults. Adoptive T cells engineered …
ALL) represents an unmet medical need in children and adults. Adoptive T cells engineered …
Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: state of the art and future directions
U Greenbaum, KM Mahadeo, P Kebriaei… - Frontiers in …, 2020 - frontiersin.org
Use of adoptive T-cell therapy modified with chimeric antigen receptor (CAR-T) has
revolutionized treatment of patients with relapsed/refractory (r/r) B-cell acute lymphoblastic …
revolutionized treatment of patients with relapsed/refractory (r/r) B-cell acute lymphoblastic …
CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
AH Almaeen, M Abouelkheir - Biomedicines, 2023 - mdpi.com
The currently available treatment for acute lymphoblastic leukemia (ALL) is mainly
dependent on the combination of chemotherapy, steroids, and allogeneic stem cell …
dependent on the combination of chemotherapy, steroids, and allogeneic stem cell …
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia
A Viardot, E Sala - Expert Opinion on Investigational Drugs, 2021 - Taylor & Francis
Introduction The anti-CD19 immunotherapy for the treatment of B-precursor acute
lymphoblastic leukemia (B-ALL) underwent an expansion in the last decade. CD19 is widely …
lymphoblastic leukemia (B-ALL) underwent an expansion in the last decade. CD19 is widely …
Multi-targeted immunotherapeutics to treat B cell malignancies
The concept of multi-targeted immunotherapeutic systems has propelled the field of cancer
immunotherapy into an exciting new era. Multi-effector molecules can be designed to …
immunotherapy into an exciting new era. Multi-effector molecules can be designed to …
Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR T-Cell Therapy
H Shalabi, NN Shah - Chimeric Antigen Receptor T-Cell Therapies for …, 2020 - Elsevier
CAR T-cell–therapy represents a promising therapeutic option in patients with
relapsed/refractory B-cell malignancies. However, despite encouraging remission induction …
relapsed/refractory B-cell malignancies. However, despite encouraging remission induction …
[HTML][HTML] Game changers in pediatric cancer
J De Lartigue - J. Community Support. Oncol., 2018 - mdedge.com
Game changers in pediatric cancer | Journal of Clinical Outcomes Management Skip to main
content Home Journal of Clinical Outcomes Management ALL Specialities ALL Specialities …
content Home Journal of Clinical Outcomes Management ALL Specialities ALL Specialities …
CAR T-Cell Therapy for CNS Malignancies
Chimeric antigen receptor (CAR) T-cell immunotherapy has emerged as a potential option
for the treatment of central nervous system (CNS) malignancies. Despite encouraging …
for the treatment of central nervous system (CNS) malignancies. Despite encouraging …
Generation and functional comparison of anti-CD20 chimeric antigen receptors
RH Britton - 2019 - eprints.soton.ac.uk
Chimeric antigen receptor (CAR) T-cell therapy has proven effective, particularly in targeting
relapsed, refractory haematological malignancies. However, optimal CAR design is not fully …
relapsed, refractory haematological malignancies. However, optimal CAR design is not fully …